A carregar...
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
PURPOSE: To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL). PATIENTS AND METHODS: Eligible patients had relapsed/refractory HCL after ≥ two prior therapies and...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383181/ https://ncbi.nlm.nih.gov/pubmed/22355053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.1756 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|